Pathophysiology of Type 2 diabetes and modes of action of therapeutic interventions

Archives of Internal Medicine

Volumn 157, Issue 16, 1997, Pages 1802-1817

  Dagogo Jack, Samuel ^a   Santiago, Julio V ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [(2 HYDROXY 2 PHENYLETHYL)AMINO]PROPYL]BENZOIC ACID METHYL ESTER HYDROGEN MALEATE; 4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; 4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID METHYL ESTER; ACARBOSE; ACETIC ACID DERIVATIVE; ACETOHEXAMIDE; ACIPIMOX; AGENTS AFFECTING CARBOHYDRATE METABOLISM; AGENTS AFFECTING LIPID METABOLISM; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRONCHODILATING AGENT; CALCIUM ANTAGONIST; CARBOXYLIC ACID DERIVATIVE; CHLORPROPAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ESTROGEN; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; INSULIN; INSULIN LISPRO; METFORMIN; MONOAMINE OXIDASE INHIBITOR; ORAL ANTIDIABETIC AGENT; ORAL CONTRACEPTIVE AGENT; SDZ CPI 975; SULFONYLUREA DERIVATIVE; TOLAZAMIDE; TOLBUTAMIDE; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CARDIOTOXICITY; CLINICAL TRIAL; DIABETIC MICROANGIOPATHY; DRUG COST; DRUG EFFECT; GASTROINTESTINAL SYMPTOM; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; INSULIN TREATMENT; LACTIC ACIDOSIS; LIVER METABOLISM; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030768371     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.16.1802     Document Type: Review

References (181)

1. Flier JS. Syndrome of insulin resistance: from patient to gene and back again. Diabetes. 1992; 41:1207-1219.
2. Polonsky KS, Sturis J, Bell GI. Non-insulin-dependent diabetes mellitus: a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med. 1996;334: 777-783.
3. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
4. Gelding SV, Goldham N, Niththyananthan R, Anyaoku V, Johnston DG. Insulin resistance with respect to lipolysis in non-diabetic relatives of European patients with type 2 diabetes. Diabet Med. 1995;12:66-73.
5. Eriksson J, Franssila-Kallunki A, Ekstrand A, et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med. 1989;321:337-343.
6. Beck-Nielsen H, Groop LC. Metabolic and genetic characterization of prediabetic states. J Clin Invest. 1994;94:1714-1721.
7. Randle PJ, Kerby AL, Espinal J. Mechanisms decreasing glucose oxidation in diabetes and starvation: role of lipid fuels and hormones. Diabetes Metab Rev. 1988;4:623-638.
8. Chen Y-D, Golay A, Swislocki A, Reaven G. Resistance to insulin suppression of plasma free fatty acid concentrations and insulin stimulation of glucose uptake in non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1987;64:17-21.
9. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor α in human obesity and insulin resistance. J Clin Invest. 1995;95: 2409-2415.
10. White MF, Kahn CR. The insulin signaling system. J Biol Chem. 1994;269:1-4.
11. Quon MJ, Butte AJ, Zarnowski MJ, et al. Insulin receptor substrate 1 mediates the stimulatory effect of insulin on GLUT4 translocation in transfected rat adipose cells. J Biol Chem. 1994;269: 27920-27924.
12. Araki E, Lipes MA, Patti ME, et al. Alternative pathway of insulin signaling in mice with targeted disruption of IRS-1 gene. Nature. 1994;372:186-190.
13. Ravindra R, Caro JF. Insulin stimulates GDP release from G proteins in the rat and human liver plasma membranes. J Cell Biochem. 1993;53: 181-189.
14. Caro J. Biochemical defects of insulin action in humans. In: LeRoith D, Taylor SI, Olefsky JM, eds. Diabetes Mellitus: A Fundamental and Clinical Text. Philadelphia, Pa: JB Lippincort; 1996: 519-529.
15. Freidenberg GR, Reichart D, Olefsky JM, Henry RR. Reversibility of defective adipocyte insulin receptor kinase activity in non-insulin-dependent diabetes mellitus. J Clin Invest. 1988;82:1389-1406.
16. Dohm GL, Elton CW, Raju MS, et al. IGF-I-stimulated transport in human skeletal muscle and IGF-I resistance in obesity and NIDDM. Diabetes. 1990;39:1028-1032.
17. Goodyear LJ, Giorgino F, Sherman LA, Carey J, Smith RJ, Dohm GL. Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. J Clin Invest. 1995;95: 2195-2204.
18. Choi WH, O'Rahilly S, Buse JB, et al. Molecular scanning of the insulin-responsive glucose transporter (GLUT4) gene in NIDDM subjects. Diabetes. 1991;40:1712-1718.
19. Dela F, Ploug T, Handberg A, et al. Physical training increases muscle GLUT4 protein and mRNA in patients with NIDDM. Diabetes. 1994;43:862-865.
20. Mandarino LJ. Regulation of skeletal muscle pyruvate dehydrogenase and glycogen synthase in man. Diabetes Metab Rev. 1989;5:475-486.
21. Henry RR, Thorburn AW, Beerdsen P, Gumbiner B. Dose-response characteristics of impaired glucose oxidation in noninsulin-dependent diabetes mellitus. Am J Physiol. 1991;261:E132-E140.
22. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in adipose tissue: regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest. 1995;95:2111-2119.
23. Norman RA, Bogardus C, Ravussin E. Linkage between obesity and a marker near the tumor necrosis factor α locus in Pima Indians. J Clin Invest. 1995;96:158-162.
24. Lang CH, Dobrescu C, Bagby DJ. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology. 1992;130:43-52.
25. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha and obesity-induced insulin resistance. Science. 1996;271:665-668.
26. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259:87-91.
27. Hotamisligil GS, Budavari A, Murray DL, Spiegelman BM. Reduced tyrosine activity of the insulin receptor in obesity-diabetes: central role of tumor necrosis factor-α. J Clin Invest. 1994;94: 1543-1549.
28. Elbein SC, Chiu KC, Hoffman MD, Mayorge RA, Bragg KL, Leppert MF. Linkage analysis of 19 candidate regions for insulin resistance in familial NIDDM. Diabetes. 1995;44:1259-1265.
29. Ward WK, Beard JC, Porte D Jr. Clinical aspects of islet β-cell function in non-insulin-dependent diabetes mellitus. Diabetes Metab Rev. 1986;2: 297-313.
30. Luzi L, DeFronzo RA. Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. Am J Physiol. 1989;257:E241-E246.
31. Porte D. β-cells in type II diabetes mellitus. Diabetes. 1991;40:166-180.
32. Leahy JL. Natural history of β-cell dysfunction in NIDDM. Diabetes Care. 1990;13:992-1010.
33. Porte D, Kahn SE. Hyperproinsulinemia and amyloid in NIDDM: clues to etiology of islet β-cell dysfunction? Diabetes. 1989;38:1333-1336.
34. O'Rahilly S, Turner RC, Matthews DR. Impaired pulsatile secretion of insulin in relatives of patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1988;318:1225-1230.
35. Kosaka K, Kuzuya T, Akanuma Y, Hagura R. Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment. Diabetologia. 1980;18:23-28.
36. Vague P, Moulin J-P. The defective glucose sensitivity of the beta-cell in noninsulin dependent diabetes: improvement after twenty hours of normoglycemia. Metabolism. 1982;31:139-142.
37. Yoshioka N, Kuzuya T, Matsuda A, Iwamoto Y. Effects of dietary treatment on serum insulin and pro-insulin response in newly diagnosed NIDDM. Diabetes. 1989;38:262-266.
38. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR. Role of glucose and insulin resistance in development of type 2 diabetes: result of a 25-year follow-up study. Lancet. 1992;340:925-929.
39. Nicholls JSD, Chan SP, Ali K, Beard RW, Dornhorst A. Insulin secretion and sensitivity in women fulfilling WHO criteria for gestational diabetes. Diabet Med. 1995;12:56-60.
40. Montana E, Bonner-Weir S, Weir GC. Transplanted beta cell response to increased metabolic demand. J Clin Invest. 1994;93:1577-1582.
41. Groop LC, Bottazzo GF. Genetic susceptibility to non-insulin-dependent diabetes mellitus. Diabetes. 1986;35:237-241.
42. Vaag A, Henriksen JE, Madsbad S, Holm N, Beck-Nielsen H. Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus. J Clin Invest. 1995;95:690-698.
43. Froguel P, Zouali H, Vionnet N, et al. Familial hyperglycemia due to mutations in the glucokinase gene. N Engl J Med. 1992;328:697-702.
44. Byrne MM, Sturis J, Clement K, et al. Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations. J Clin Invest. 1994;93:1120-1130.
45. Matchinsky F, Liang Y, Kesavan P, et al. Glucokinase as pancreatic β-cell glucose sensor and diabetes gene. J Clin Invest. 1993;92:2092-2098.
46. + channels in the control of glucose-induced electrical activity in pancreatic β cells. Pflugers Arch. 1990;416:568-572.
47. + channels in pancreatic β-cells. Nature. 1984; 311:271-273.
48. Misler S, Giebisch G. ATP-sensitive potassium channels in physiology, pathophysiology, and pharmacology. Curr Opin Nephrol Hypertens. 1992;1: 21-33.
49. + channels. Science. 1995;268:372-373.
50. Aguilar-Bryan L, Nichols CG, Wechler SW, et al. Cloning of the β cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science. 1995;268:423-426.
51. KATP: need for an inward rectifier of ion channels and sulfonylurea receptor. Science. 1995;270:1166-1170.
52. Thomas PM, Cote GJ, Wohllk N, et al. Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. Science. 1995;268:426-429.
53. Inoue H, Ferrer J, Welling C, et al. Sequence variants in the sulfonylurea receptor (SUR) gene are associated with NIDDM in Caucasians. Diabetes. 1996;45:825-831.
54. Kadowaki T, Kadowaki H, Mori Y, et al. A subtype of diabetes mellitus associated with a mutation of mitochondrial DNA. N Engl J Med. 1994;330:962-967.
55. Gulli G, Ferrannini ETL, Stern M, Haffner S, DeFronzo R. The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents. Diabetes. 1992;41:1575-1587.
56. Hue L. Gluconeogenesis and its regulation. Diabetes Metab Rev. 1987;3:111-126.
57. WHO Expert Committee on Diabetes Mellitus. Second Report, WHO Technical Report Series No. 646. Geneva, Switzerland: World Health Organization; 1980.
58. Long SD, O'Brien K, MacDonald KG Jr, et al. Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes: a longitudinal interventional study. Diabetes Care. 1994;17:372-375.
59. Antonucci T, Whitcomb R, McLain R, Lockwood D. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care. 1997;20:188-193.
60. Kaiser N, Corcos AP, Sarel I, Cerasi E. Monolayer culture of adult rat pancreatic islets on extracellular matrix: modulation of β-cell function by chronic exposure to high glucose. Endocrinology. 1991;129:2067-2076.
61. Davalli AM, Ricordi C, Socci C, et al. Abnormal sensitivity to glucose of human islets cultured in a high glucose medium: partial reversibility after an additional culture in a normal glucose medium. J Clin Endocrinol Metab. 1991;72:202-208.
62. Robertson RP, Olsen LK, Zhang H-J. Differentiating glucose toxicity from glucose desensitization: a new message from the insulin gene. Diabetes. 1994;43:1085-1089.
63. De Fronzo RA, Ferrannini F. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991;14:173-194.
64. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes. 1994;43:104-109.
65. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study VIII: study design, progress and performance. Diabetologia. 1991;34:877-890.
66. 1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes. 1992;41:202-208.
67. Nathan DM. Long-term complications of diabetes mellitus. N Engl J Med. 1993;328.1676-1685.
68. Kussman MJ, Gildstein HH, Gleason RE. The clinical course of diabetic nephropathy. JAMA. 1976; 236:1861-1863.
69. Gall M-A, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving H-H. Albuminuria and poor metabolic control predict mortality in NIDDM. Diabetes. 1995;44:1303-1309.
70. Ellenberg M. Diabetic neuropathiccachexia. Diabetes. 1974;23:418-423.
71. Dagogo-Jack SE, Craft S, Cryer PE. Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. J Clin Invest. 1993; 91:819-828.
72. Fanelli CG, Epifano L, Rambotti AM, et al. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of the neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes. 1993;42:1683-1689.
73. Dagogo-Jack S, Rattarasarn C, Cryer PE. Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. Diabetes. 1994;43:1426-1434.
74. Jacoby RM, Nesto RW. Acute myocardial infarction in the diabetic patient: pathophysiology, clinical course, and prognosis. J Am Coll Cardiol. 1992; 20:736-744.
75. Said G, Goulon-Goeau C, Slama G, Tchobroutsky G. Severe early-onset polyneuropathy in insulin-dependent diabetes mellitus: a clinical and pathological study. N Engl J Med. 1992;326:1257-1263.
76. Pettitt DJ, Saad MF, Bennett PM, Nelson RG, Knowler WC. Familial predisposition to renal disease in two generations of Pima Indians with type II (non-insulin-dependent) diabetes mellitus. Diabetologia. 1990;33:438-443.
77. Greene DA, Lattimer SA, Sima AAF. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med. 1987;316:599-606.
78. Vlassara H. Receptor-mediated interaction of advanced glycosylation end products with cellular components within diabetic tissues. Diabetes. 1992;41(suppl 2):52-56.
79. Hostetter TH. Diabetic nephropathy, metabolic versus hemodynamic considerations. Diabetes Care. 1992;15:1205-1215.
80. Sharp PS. Growth factors in the pathogenesis of diabetic retinopathy. Diabetes Rev. 1995;3:164-176.
81. Engerman RL. Pathogenesis of diabetic retinopathy. Diabetes. 1989;38:1203-1206.
82. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 1997;20(suppl 1):5-13.
83. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:978-986.
84. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
85. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol. 1995;75:894-903.
86. Despres J-P, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334: 952-957.
87. Genuth S. Exogenous insulin administration and cardiovascular risk in NIDDM and IDDM. Ann Intern Med. 1996;124:104-109.
88. Colwell JA. The feasibility of intensive insulin management in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996;124:131-135.
89. Bressler R, Johnson DG. Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus. Arch Intern Med. 1997;157:836-848.
90. Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS. Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med. 1991;325:147-152.
91. Horton ES. Exercise and physical training: effects on insulin sensitivity and glucose metabolism. Diabetes Metab Rev. 1986;2:1-17.
92. Rogers MA, Yamamoto C, King DS, Hagberg JM, Ehsani AA, Holloszy JO. Improvement in glucose tolerance after one week of exercise in patients with mild NIDDM. Diabetes Care. 1988;11:613-618.
93. Despres J-P, Pouliot M-C, Moorjani S, et al. Loss of abdominal fat and metabolic response to exercise training in obese women. Am J Physiol. 1991;261:E159-E167.
94. Eriksson KF, Lindgarde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. Diabetologia. 1991;34: 891-898.
95. Grundy SM. Dietary therapy in diabetes mellitus: is there a single best diet? Diabetes Care. 1991; 14:796-801.
96. Henry RR, Wallace P, Olefsky JM. Effect of weight loss on mechanisms of hyperglycemia in obese non-insulin-dependent diabetes mellitus. Diabetes. 1986;35:990-998.
97. Stunkard AJ. Current views on obesity. Am J Med. 1996;100:230-236.
98. American Diabetes Association. Nutritional recommendations and principles for people with diabetes mellitus. Diabetes Care. 1997;20(suppl 1): 14-17.
99. Groop LC. Sulfonylureas in NIDDM. Diabetes Care. 1992;15:737-754.
100. Rosenstock J, Samols E, Muchmore DB, Schneider J, The Glimepiride Study Group. Glimepiride, a new once-daily sulfonylurea: a double-blind placebo-controlled study of NIDDM patients. Diabetes Care. 1996;19:1194-1199.
101. Groop L, Schalin C, Franssila-Kallunki A, Widen E, Ekstrand A, Eriksson J. Characteristics of non-insulin-dependent diabetic patients with secondary failure to oral antidiabetic therapy. Am J Med. 1989;87:183-190.
102. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes. 1970;19:789-830.
103. Kilo C, Miller JP, Williamson JR. The Achilles heel of the University Group Diabetes Program. JAMA. 1980;243:450-457.
104. Paasikivi J, Wahlberg F. Preventive tolbutamide treatment and arterial disease in mild hyperglycemia. Diabetologia. 1971;7:323-327.
105. Sator G, Schersten B, Carlstrom S, Melander AS, Norden A, Persson G. Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes. 1980;29:41-49.
106. Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes. 1985;34:222-234.
107. Ducimetriere P, Eschwege E, Papoz L, Richard JL, Claude JR, Rosselin G. Relationship between plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia. 1980;19:205-210.
108. Stern MP. Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents? Ann Intern Med. 1996;124:110-116.
109. Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS. Intensive conventional insulin therapy for type II diabetes: metabolic effects during a 6-mo outpatient trial. Diabetes Care. 1993;16:21-31.
110. Howey DC, Bowsher RR, Brunelle RL, et al. [Lys (B28), Pro (B29)]-human insulin: effect of injection time on postprandial glycemia. Clin Pharmacol Ther. 1995;58:459-469.
111. Burge MR, Castillo KR, Schade DS. Meal composition is a determinant of lispro-induced hypoglycemia in IDDM. Diabetes Care. 1997;20:152-155.
112. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574-579.
113. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects: a study of two ethnic groups. Diabetes Care. 1993;16:621-629.
114. Wu MS, Johnson P, Sheu WHH, et al. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care. 1990;13: 1-8.
115. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:550-554.
116. DeFronzo RA, Goodman AM, Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:541-549.
117. Dandona P, Fonseca V, Mier A, Beckett AG. Diarrhea and metformin in a diabetic clinic. Diabetes Care. 1983;6:472-474.
118. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf. 1994;11:223-241.
119. Innerfield RJ. Metformin-associated mortality in US studies. N Engl J Med. 1996;334:1611-1613.
120. United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 16: progressive nature of type 2 diabetes. Diabetes. 1995;44:1249-1258.
121. Chiasson J-L, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann Intern Med. 1994;121:928-935.
122. Coniff RF, Shapiro JA, Seaton TB, Bray GA. Multicenter, placebo-controlled trial comparing acarbose (Bay b 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med. 1995;98: 443-451.
123. Bressler R, Johnson D. New pharmacological approaches to therapy of NIDDM. Diabetes Care. 1992;15:792-805.
124. Lehman JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ) J Biol Chem. 1995;270:12953-12956.
125. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 1996;45:1661-1669.
126. Suter SL, Nolan JJ, Wallace P, et al. Metabolic effects of new oral hypoglycemic agent troglitazone in NIDDM subjects. Diabetes Care. 1992;15:193-203.
127. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med. 1994;331:1188-1193.
128. Iwamoto Y, Kosaka K, Akanuma Y, Shigeta Y, Kaneko T. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care. 1996;19:151-156.
129. Foley JE. Rationale and application of fatty acid oxidation inhibitors in treatment ot diabetes mellitus. Diabetes Care. 1992;15:773-784.
130. Petrie JR, Donelly R. New pharmacological approaches to insulin and lipid metabolism. Drugs. 1994;47:701-710.
131. Valera A, Rodriguez-Gil J, Bosch F, et al. Vanadate treatment restores the expression of genes from key enzymes in the glucose and ketone bodies metabolism in the liver of diabetic rats. J Clin Invest. 1993;22:4-11.
132. Stacpoole PW, Greene Y. Dichloroacetate. Diabetes Care. 1992;15:785-791.
133. Jahoor F, Zhang XJ, Frazer E. Mechanism by which dichloroacetate lowers lactic acid levels: the kinetic interrelationships between lactate, pyruvate, alanine, and glucose. Proc Soc Exp Biol Med. 1994;205:44-51.
134. Thiebaud D, DeFronzo RA, Jacot E, et al. Effect of long chain triglyceride infusion on glucose metabolism in man. Metab Clin Exp. 1982;31:1128-1136.
135. Balasse EO, Neef MA. Influence of nicotinic acid on the rates of turnover and oxidation of plasma glucose in man. Metab Clin Exp. 1973;22:1193-1204.
136. Garg A, Grundy SM. Nicotinic acid as a therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA. 1990;264:723-726.
137. Fulcher GR, Walker M, Catalano C, Agius L, Alberti KG. Metabolic effects of suppression of non-esterified fatty acid levels with acipimox in obese NIDDM subjects. Diabetes. 1992;41:1400-1408.
138. Dean JD, McCarthy S, Betteridge DJ, Whately-Smith C, Powell J, Owens DR. The effect of acipimox in patients with type 2 diabetes and persistent hyperlipidaemia. Diabet Med. 1992;9:611-615.
139. Fulcher GR, Catalano C, Walker M, et al. A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with type 2 diabetes mellitus. Diabet Med. 1992;9:908-914.
140. Collier GR, Traianedes K, Macaulay SL, O'Dea K. Effect of fatty acid oxidation inhibition on glucose metabolism in diabetic rats. Horm Metab Res. 1993;25:9-12.
141. Foley JE, Anderson R. Fatty acid oxidation inhibitors. In: LeRoith D, Taylor SI, Olefsky JM, eds. Diabetes Mellitus: A Fundamental and Clinical Text. Philadelphia, Pa: JB Lippincott; 1996:668-674.
142. Lee SM, Bahl JJ, Bressler R. Prevention of the metabolic effects of 2-tetradecylglycidate by octanoic acid in the genetically diabetic mouse (db/ db). Biochem Med. 1985;33:104-109.
143. Haeckel R, Ollerich M, Binder L. Hydrazonopropionic acids derivatives. In: Bailey CJ, Flatt PR, eds. New Antidiabetic Drugs. London, England: Smith Gordon: 1990:207-216.
144. Swartzentruber MS, Harris RA. Inhibition of metabolic processes by coenzyme-A-sequestering aromatic acids. Biochem Pharmacol. 1987;36:3147-3153.
145. Young DA, Ho RS, Bell PA, et al. Inhibition of hepatic glucose production by SDZ 51641. Diabetes. 1990;39:1408-1413.
146. 3-adrenergic receptor. Science. 1990;245:1118-1121.
147. 3-receptors in rat adipocytes. Br J Pharmacol. 1989;98:1420-1424.
148. Widen E, Lehto M, Kanninen T, Walston J, Shuldiner AR, Groop LC. Association of a polymorphism in the β3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. N Engl J Med. 1995;333:348-351.
149. 3-adrenergic receptor gene is associated with obesity and hyperinsulinemia in Japanese subjects. Biochem Biophys Res Commun. 1995;215:555-560.
150. 3-adrenergic-receptor gene. N Engl J Med. 1995;333:343-347.
151. Cawthorne MA, Sennitt MV, Arch JS, Smith SA. BRL 35135: a potent and selective atypical β-adrenoceptor agonist. Am J Clin Nutr. 1992;55 (suppl 1):252S-257S.
152. Connacher AA, Jung RT, Mitchell PEG. Weight loss in obese subjects given BRL 26830A, a new atypical β-adrenoceptor agonist. BMJ. 1988;296:1217-1220.
153. Yki-Jarvinen H, Kauppila M, Kujansuu E, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1992;327:1426-1433.
154. Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes: a meta-analysis of the randomized placebo-controlled trials. Arch Intern Med. 1996;156: 259-264.
155. Haupt E, Knick B, Koschinsky T, Liebermeister H, Schneider J, Hirche H. Oral antidiabetic combination therapy with sulfonylureas and metformin. Diabetes Metab. 1991;17:224-231.
156. Hermann LS, Schersten B, Bitzen PO, Kjellstrom T, Lindgarde F, Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: a double-blind controlled study. Diabetes Care. 1994;17:1100-1109.
157. Giugliano D, Quatraro A, Consoli G, et al. Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol. 1993;44:107-112.
158. Leblanc H, Marre M, Billault B, Passa PH. Combined continuous subcutaneous insulin infusion in 10 overweight insulin requiring diabetic patients. Diabetes Metab. 1987;13:613-617.
159. Hermann LS. Metformin: a review of its pharmacologic properties and therapeutic use. Diabetes Metab Rev. 1979;5:233-245.
160. Reaven GM, Lardinois CK, Greenfield MS, Schwartz HC, Vreman HJ. Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled on sulfonylureas. Diabetes Care. 1990;13(suppl 3):32-36.
161. Rodier M, Richard JL, Monnier L, Mirouze J. Effect of long-term acarbose (Bay g 5421) therapy on metabolic control of non-insulin-dependent (type II) diabetes mellitus. Diabetes Metab. 1988; 14:12-14.
162. Lebovitz HE. Stepwise and combination drug therapy for the treatment of NIDDM. Diabetes Care. 1994;17:1542-1544.
163. Wandell PE, Brorsson B, Aberg H. Drug use in patients with diabetes. Diabetes Care. 1996;19:992-994.
164. Alderman MH. Which antihypertensive agent first: and why! JAMA. 1992;267:2786-2787.
165. Yusuf S, Wittes J, Probstfield J. Evaluating effects of treatment in subgroups of patients within a clinical trial: the case of non-Q-wave myocardial infarction and beta-blockers. Am J Cardiol. 1990;66:220-222.
166. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
167. Lewis EJ, Hunsicker LG, Dain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy [published correction appears in N Engl J Med. 1993;330:152]. N Engl J Med. 1993;329:1456-1462.
168. Hirsch IB, Boyle PJ, Craft S, Cryer PE. Higher glycemic thresholds for symptoms during beta-adrenergic blockade in IDDM. Diabetes. 1991; 40:1177-1186.
169. Ames RP. The effects of antihypertensive drugs on serum lipids and lipoproteins, I: diuretics. Drugs. 1986;32:260-276.
170. Ames RP. The effects of antihypertensive drugs on serum lipids and lipoproteins, II: nondiuretic drugs. Drugs. 1986;32:335-357.
171. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med. 1989;321:868-873.
172. Lithell HOL. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care. 1991;14:203-209.
173. 2+ channel antagonists, and α-adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension. Diabetes. 1995;44:665-671.
174. + currents in pancreatic B-cells. Naunyn Schmiedebergs Arch Pharmacol. 1988;337:225-230.
175. Young JB, Langsberg L. Adrenergic influence on peripheral hormone secretion. In: Kunos G, ed. Adrenoceptors and Catecholamine Action, Part B. New York, NY: John Wiley & Sons Inc; 1983:157-217.
176. Vestal RE, Eriksson CE, Musser B, Ozaki LK, Halter JB. Effect of intravenous aminophylline on plasma levels of catecholamines and related cardiovascular and metabolic responses in man. Circulation. 1983;67:162-171.
177. Guillaume-Gentil C, Assimacopoulos-Jeannet F, Jeanrenaud B. Involvement of non-esterified fatty acid oxidation in glucocorticoid-induced peripheral insulin resistance in vivo in rats. Diabetologia. 1993;36:899-906.
178. Gaspard UJ. Metabolic effects of oral contraceptives. Am J Obstet Gynecol. 1987;157:1029-1041.
179. Turner R, Cull C, Holman R, for the United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996;124:136-145.
180. American Diabetes Association. The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care. 1996;19(suppl):54-61.
181. Westphal SA. The occurrence of diabetic ketoacidosis in non-insulin-dependent diabetes and newly diagnosed diabetic adults. Am J Med. 1996; 101:19-24.